Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg raises target price on Volution

(Sharecast News) - Over at Berenberg, analysts hiked their target price on ventilation equipment business Volution to 600.0p from 500.0p on Wednesday following the group's full-year trading update. Berenberg stated that while the macro backdrop has "remained challenging" given subdued levels of new construction activity, high interest rates and weak consumer confidence, Volution has continued to be "resilient", with management confident about the brands and strategy.

Overall revenue for FY24 was up by 7% year-on-year in constant currency terms, of which slightly over 1% was organic growth.

As the German bank flagged back in March, key focus points were the strength of the outperformance in Volution's UK residential division, a resilient performance in Europe given the market weakness, further delivery of strong adjusted underlying earnings margins, and very clean cash conversion that leaves the business at 0.5x EBITDA pre-leases and well positioned for future consolidation.

"With the company guiding to a 'slight' increase in adjusted earnings per share versus prevailing consensus expectations, we increase our FY24 numbers by circa 1.5%," said Berenberg, which has a 'buy' rating on the stock.

"As such, with Volution shares also performing well and recently breaking through our prevailing 500,0p price target, we have increased our price target to 600.0p to reflect this change in peer multiples, and our ongoing confidence both in the company's strategy and its ability to participate in the expected recovery in end-market demand."

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

Berenberg lowers target price on Impax Asset Management
(Sharecast News) - Analysts at Berenberg lowered their target price on Impax Asset Management from 620.0p to 560.0p on Tuesday but noted that outflows had started to slow.
GSK's Arexvy provides protection over three RSV seasons, trial shows
(Sharecast News) - GSK has announced positive results from a phase III trial of its Arexvy RSV vaccine, showing that just one dose of the treatment could help protect older adults at risk of RSV disease over three seasons.
S&U revenue up, profitability a challenge in first half
(Sharecast News) - Motor and property finance specialist S&U reported a mixed first-half financial performance on Tuesday, after group revenue increased 9% year-on-year to £60.4m.
Loungers reports slight slowdown in LFL sales growth
(Sharecast News) - Cosy Club owner Loungers reported a slight slowdown in like-for-like sales growth on Tuesday and a jump in revenue.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.